FormFactor (FORM.US) Buffett Framework Deep-Dive Research

Cost structure and dependencies. Costs mainly include manufacturing materials, employee compensation, manufacturing overhead, shipping, warranty, and inventory write-down provisions. The company's manufacturing also depends on a small number of suppliers, and in some cases sole-source suppliers, for items such as printed circuit board assemblies, plating materials, and ceramic substrates. In 2025, the company stated clearly that tariff costs reduced overall gross margin by 1.4 percentage points. Meanwhile, the cost structure is not purely variable. When scale rises, gross margin and expense ratios can improve; when scale falls, fixed costs weigh on profitability. This is the typical industrial equipment/consumables pattern: operating leverage on the way up and faster profit contraction on the way down.

Industry position and competitive landscape. In its 2026 investor presentation, the company positions itself in "wafer test and measurement": upstream from final packaging test systems, downstream from front-end wafer fabrication equipment, and focused on the critical test interface connecting ATE to wafers as well as engineering-stage test systems. The company's cited framework suggests its served market consists of advanced probe cards and engineering systems, totaling about $2.75 billion in 2024, including about $2.25 billion in advanced probe cards. The advanced probe-card market is expected to reach $2.6 billion in 2027, with a CAGR above 7%. SEMI also expects global semiconductor test equipment to grow 48.1% in 2025 and another 12.0% in 2026, indicating that industry momentum is indeed improving.

Main competitors and industry attractiveness. This is not a monopoly industry. Direct probe-card competitors include at least Technoprobe and Micronics. Technoprobe's official materials describe it as the world leader in probe cards by both volume and revenue. Micronics' official medium-term plan states that it had about 12% share of the probe-card industry in 2022 and held an overwhelming number-one position in DRAM probe cards. Teradyne and Advantest sit in the adjacent test platform/interface ecosystem. Teradyne even invested in Technoprobe and formed a strategic partnership with it, showing that the industry is not dominated by FORM alone. It is a long-term contest among a few strong players around customer roadmaps, yield, throughput, and speed of design-in. Industry attractiveness should therefore be rated above average: long-term demand is supported by chip complexity and AI infrastructure, but cyclicality, technology substitution, and customer bargaining power cannot be ignored.

Moat judgment. FormFactor's moat is not consumer brand mindshare or network effects. It is closer to a combination of customer relationships + engineering know-how + early participation in customer roadmaps + global delivery capability. The company emphasizes four points in its presentation materials: early customer engagement, application and technology leadership, world-class lead times and quality, and the largest R&D budget in its served market. In the TechInsights 2025 customer satisfaction survey, the company was ranked global number one in both test subsystems and focused chip manufacturing equipment. The company also received SK hynix's Best Partner Award, with the award explicitly referencing core use cases such as HBM and advanced packaging test. These facts show that FormFactor has a real position in technology and execution. The issue is that these strengths look more like a moderately wide moat that requires continuous investment to maintain than a moat like Coca-Cola's brand, which can widen even while the company does relatively little.

Based on the above, I assign the following scores:

These scores are based on the company's 10-K, 2026 presentation materials, official competitor materials, and industry organization forecasts.

Would I be willing to hold this business if the stock market closed for five years. At a reasonable price, yes; at the current price, no. The reason is straightforward: the business itself can be held, but buying at today's price requires simultaneous optimism about strong HBM demand, a step-change in margins, maintenance of competitive position, and no compression in a high valuation. That is no longer a typical low-risk, slow-odds investment.

Management and Capital Allocation

Whether management is honest, rational, and long-term oriented. CEO Mike Slessor has served as CEO since 2014 and came from MicroProbe, which FormFactor acquired. His tenure is long and closely tied to the core probe-card business. In the company's incentive structure, 70% of short-term incentives depend on financial performance and 30% on company goals. Long-term PRSUs are based on TSR, creating, at least on the surface, a dual constraint of financial targets and shareholder returns. The company also has stock ownership guidelines and clawback provisions, all of which are positive governance items.

But management is not a heavily invested owner. This point matters. The 2026 proxy statement shows that the CEO beneficially owned about 487,000 shares, which is meaningful in absolute terms but still below 1% of the company. All current directors and executives together owned about 615,000 shares, also below 1%. That means alignment with shareholders comes more from compensation design and job attachment than from an owner-operator structure where a large portion of net worth is tied to company stock. For conservative value investors, this lowers the management assessment from "strongly aligned" to "neutral to positive."

Capital allocation has to be split into parts. On the positive side, the company completed two fairly good divestitures. In 2023, it sold the FRT business to Camtek for about $100.1 million in net cash, while the total consideration when it bought that business in 2019 was about $24.4 million. In 2024, it sold its China operating entity for about $21.4 million in net proceeds, generating about $20.3 million in pre-tax gain. This suggests management can make portfolio-level subtractions instead of blindly holding every business. On the other hand, the company invested about $67.16 million in FICT in 2025, with a year-end carrying value of $64.10 million, and recorded a $2.02 million equity-method loss. The Keystone Photonics acquisition was only $20.60 million, too small to judge clearly. Overall, capital allocation is not poor, but it has not yet proven top-tier either.

Buybacks, dividends, and dilution. The company pays no dividend. Cash is mainly used for reinvestment, acquisitions, facility expansion, and modest buybacks. In 2025, the two categories of buybacks totaled about $26.20 million, including about 665,000 shares for about $22.10 million under the earlier program and about 135,000 shares for about $4.10 million under the new plan. In Q1 2026, the company did not continue buybacks. The company states explicitly that the main purpose of the new buyback plan is to offset potential dilution from equity compensation, which is not the same as aggressive share retirement when shares are undervalued. Meanwhile, the 2026 annual meeting approved an additional 5 million shares for issuance under the 2012 equity incentive plan. The proxy statement disclosed that, based on historical grant pace, the related overhang was about 11.3%, and the average burn rate over the past three years was about 1.43%. Therefore, although FORM's share count has not expanded out of control, management is also not an extremely restrained "per-share value" repurchaser.

One reservation on compensation metrics. The proxy statement shows that adjusted operating income used for compensation assessment excludes amortization, inventory and fixed-asset fair value adjustments, stock-based compensation expense, restructuring costs, net gains on business divestitures, acquisition-related costs, and other items. For operating assessment, such adjustments may not be unreasonable. But for owners, SBC and acquisition costs are not costs that automatically disappear. This keeps me cautious in scoring management and capital allocation.

The overall assessment is as follows:

These judgments are mainly based on the 2026 proxy statement, the 2025 10-K, and the 2026 annual meeting 8-K.

Financial Quality and Owner Earnings

Start with the past few years: the conclusion matters more than the story. The key financial data below are summarized based on the company's GAAP disclosures. 2020-2022 data come from the 2022 10-K; 2023-2025 data come from the 2025 10-K; Q1 2026 is from the latest 10-Q. Capital expenditure is cash paid for property, plant, and equipment.

• Q1 2026 free cash flow here is approximated as operating cash flow minus capital expenditure; management's free cash flow figure was $30.70 million.

How to read this table. First, revenue growth has not been as "linearly impressive" as the share price performance. From 2020 to 2025, revenue increased from $694 million to $785 million, a total gain of only about 13%. The real strength is concentrated mainly from the second half of 2024 to the first half of 2026, especially in DRAM/HBM. Second, gross margin has long fluctuated in the 39%-42% range and has not shown sustained expansion. In 2025, the company even stated clearly that tariff costs reduced overall gross margin by 1.4 percentage points. Third, free cash flow is highly volatile: it was only about $8.6 million in 2023 and about $11.7 million in 2025, showing that this is not a machine that steadily prints cash. It is a hard-tech company with cash creation capability across the cycle, but one that can also suddenly look much less profitable because of facility expansion, inventory, and receivables absorption.

Profit quality needs adjustment. GAAP operating income in 2023 and 2024 included about $72.95 million and $20.58 million, respectively, of gains on business divestitures. Without adjustment, operating quality would be overstated. Conversely, 2025 included a $2.026 million equity investment loss from FICT and $3.025 million of new facility start-up costs, while Q1 2026 included $7.074 million of factory start-up costs, meaning GAAP profit was also depressed by short-term ramp factors. Put simply, FORM's accounting profit is not distorted, but it is very easily disturbed by asset-sale gains and temporary start-up costs. Investors must separate "reported profit" from "sustainable earnings power."

Cash flow and working capital. Operating cash flow in 2025 was $115.4 million, mainly consumed by higher inventory and receivables. The company disclosed that net working capital absorbed about $43 million that year, including an increase of about $20.16 million in receivables and about $20.66 million in inventory. This is consistent with the high growth in Q1 2026, but it also reminds us that the company's growth is not a light-capital, low-working-capital model. On inventory, year-end 2025 inventory was $110.9 million, higher than $101.7 million in 2024. The company recorded about $14.90 million of inventory write-downs/impairments that year, and KPMG listed the assessment of excess and obsolete inventory as a critical audit matter. For conservative investors, this is not evidence of fraud, but it is an important profit-quality variable to monitor.

Balance sheet and survivability. As of the end of Q1 2026, the company had about $303 million in cash and short-term/long-term marketable securities, only about $11.80 million in long-term debt, and an unused $150 million revolving credit facility. Debt-service pressure is extremely light. Even if the industry enters a downturn, the company is more likely to experience profit compression than a financial crisis. This is very important: FormFactor's main risk is not a leverage blowup, but valuation damage if the cycle weakens while the stock is highly valued.

How to think about owner earnings. Under Buffett's owner earnings framework, the hardest part is not adding back depreciation and amortization, but distinguishing maintenance capex from growth capex. In 2025, the company's capital expenditure reached $103.7 million, of which about $55 million was directly related to the new Farmers Branch manufacturing facility. Therefore, treating 2025's low free cash flow directly as the long-term norm would understate the company's medium-term earnings power. On the other hand, ignoring all of this growth capex would overstate current distributable cash. Conservatively, I prefer to view the company's current "true distributable cash capacity" for 2025-2026 as a range rather than a single point:

• Based on the 2025 audited figures, net income was about $54.36 million;

• Add back depreciation and amortization of about $37.59 million;

• Do not treat SBC as a "free cost" that can be ignored at will;

• Estimate maintenance capex at $40 million to $50 million, rather than the full $103.7 million in 2025;

• Reserve an additional $10 million to $20 million for working capital needs during the growth phase. Under this framework, my estimate of the company's current conservative owner earnings is roughly in the $80 million to $110 million range. If anti-dilution costs are further internalized under a stricter approach, the range could be lower. Under any approach, the conclusion is the same: the current share price implies a very high multiple of owner earnings.

Valuation, Margin of Safety, and Opportunity Cost

The current share price is shown below.

Several key valuation facts at the current price. As of June 9, 2026, FORM traded at about $124.25 per share, with a market capitalization of about $9.87 billion. The company's shareholders' equity at the end of Q1 2026 was about $1.059 billion, so the current P/B is about 9.3 times. The company had about $303 million in cash and marketable securities and about $12 million in total debt, making it almost net-cash, but that does not meaningfully reduce the valuation multiple. Combining full-year 2025 revenue of $785 million with Q1 2026 revenue of $226.1 million, FORM is currently an asset trading at roughly more than ten times EV/Revenue based on recent run-rate levels. Based on the real-time finance-tool metric, P/E had reached about 142.8 times.

FORM is not cheap compared with peers either. The peer comparison here is only directional because Teradyne, Cohu, and FORM do not have identical business structures: Teradyne is larger and more platform-like, while Cohu has a different segment mix and earnings quality. Even so, the current market premium for FORM's earnings is still very aggressive. Teradyne's current P/E is about 69.5 times, while FORM's is about 142.8 times; Cohu is currently loss-making. Based on latest quarterly book value, Teradyne's P/B is about 18.8 times, Cohu's is about 3.2 times, and FORM's is about 9.3 times, placing FORM in the middle. But FORM's cash-flow stability is plainly lower than that of a more mature platform company. My conclusion: FORM is neither "the cheapest among peers" nor "so high-quality that valuation can be ignored."

Method 1: owner earnings discounted valuation. I use three scenarios. The core is not to forecast the short-term share price, but to ask how much real cash this company can contribute from a long-term owner's perspective. The assumptions are:

• Conservative scenario: start with $80 million in owner earnings, grow 7% for the first five years and 3% for the next five years, use an 11% discount rate, and apply a terminal multiple of 16 times owner earnings.

• Base scenario: start with $110 million in owner earnings, grow 11% for the first five years and 4% for the next five years, use a 10% discount rate, and apply a terminal multiple of 20 times owner earnings.

• Optimistic scenario: start with $150 million in owner earnings, grow 14% for the first five years and 5% for the next five years, use a 9% discount rate, and apply a terminal multiple of 24 times owner earnings. These starting points are already well above 2025 GAAP free cash flow, and the optimistic scenario essentially treats the profitability in management's target model as sustainable. Even so, the per-share intrinsic values I get are still only about:

• Conservative range: $20-30;

• Fair range: $35-55;

• Optimistic range: $60-80. This does not mean the company is worth only that little. It means that as long as one insists on the conservative valuation discipline of owner earnings, reasonable discounting, and a normal exit multiple, it is hard to push value close to $124. The operating starting points and management targets are based on the company's 2025 10-K, Q1 2026 10-Q, and 2026 investor presentation.

Method 2: relative valuation. Here I prefer to compare with "management's own target model" rather than only with peers. The company's 2026 presentation gives a target model of $850 million in revenue, 47% non-GAAP gross margin, 22% non-GAAP operating margin, and $2.00 in non-GAAP EPS. At the current share price of $124.25, FORM is trading at about 62 times target non-GAAP EPS. If one applies 25-30 times earnings, a valuation more in line with a mature growth stock for a cyclical, highly customer-concentrated semiconductor test company that requires continuous R&D investment, the corresponding price would be only around $50-60. In other words, the current price is no longer "pricing in improvement"; it has prepaid a very large portion of that improvement.

Method 3: asset or liquidation value. This company is not well suited to a heavy-asset, resource-style replacement-cost or real-estate valuation, but the asset cushion is still worth checking. At the end of Q1 2026, the company had about $303 million in cash and marketable securities and about $291 million in net cash. Shareholders' equity was about $1.059 billion, corresponding to book value per share of about $13.6. In other words, the balance sheet is very solid, but the asset cushion comes nowhere close to supporting the current $124 share price. Therefore, FORM's valuation must come from high growth and high margins realized over many future years, not from the assets themselves.

Margin of safety judgment. In my view, the current price rests on three fragile assumptions: first, HBM and AI-related DRAM/logic demand must remain high for many years; second, Farmers Branch capacity and efficiency ramp must materially improve gross margin; third, the market must be willing to maintain an extremely high valuation multiple for a long time. If any one of these conditions fails, returns could deteriorate sharply. If two fail at the same time, the risk of permanent capital loss would rise materially. By comparison, the U.S. 10-year Treasury yield was about 4.56% on June 8, 2026. Buying FORM at the current price offers a cash return far below that level, whether measured on trailing earnings or on my relatively optimistic normalized owner earnings. What investors are really buying is the duration of distant growth, not current cash yield. This is the classic case of a good company at a bad price.

Based on the three methods above, I give the following ranges:

These are not market consensus estimates. They are valuation conclusions based on conservative value-investing discipline. The purpose is not to "guess the short term," but to refuse to pay an excessive price under high assumptions, long duration, and a high premium.

Risks, Checklist, and Final Judgment

The most important risks. First is competition risk: Technoprobe, Micronics, and others are not going away, and leading customers have the ability to pursue dual-supplier strategies. Second is technology substitution and roadmap risk: if package architectures, test methods, or customers' internal capabilities change, FORM's design-in advantage could be eroded. Third is customer concentration risk: one customer accounted for 22.9% of revenue in 2025, so profit is highly sensitive to changes in cycle or share. Fourth is supply-chain and geopolitical risk: the company depends on sole or limited suppliers for some key materials, while China customers still accounted for about 7% of revenue in 2025 and international revenue accounted for 81%; export controls, tariffs, and trade restrictions can directly affect revenue and gross margin. Fifth is execution risk: if the new facility ramp does not deliver better efficiency, start-up costs and capital expenditure will arrive first, while scale benefits may not follow. Sixth is valuation risk: this may be the biggest risk because even if operations continue improving, shareholder returns could be meaningfully pressured if valuation moves from extremely optimistic back to merely "high but normal."

The strongest bearish argument. Bears may argue that FormFactor is a high-quality components company lifted by the HBM cycle and AI compute investment boom, but the market has priced it almost like a compounder with "no cycle, ultra-high growth, strong moat, and sustainably high margins." In reality, it has no network effects, no absolute monopoly, revenue highly dependent on a few customers, quarterly revenue sensitive to same-quarter orders, historically uneven free cash flow, and GAAP operating income in 2023-2024 that benefited from nonrecurring divestiture gains. If DRAM/HBM demand cools over the next two years, customers allocate more orders to competitors, or new facility efficiency arrives slower than expected, today's high valuation will prove overly optimistic. I view this bearish argument as very strong.

What facts would overturn the investment judgment. If the following facts appear, I would concede that the current cautious valuation judgment is too conservative: first, without materially increasing dilution, the company sustains annualized revenue above $900 million to $1.0 billion for several consecutive quarters and lifts GAAP margin and free-cash-flow margin clearly above the 2024-2025 level; second, the Farmers Branch ramp clearly translates into higher gross margin and stronger cash conversion before the end of 2026; third, customer concentration declines rather than rises, while the company's leadership in HBM, advanced packaging, silicon photonics, and other new directions strengthens further. Conversely, if HBM-related DRAM revenue declines, inventory write-down provisions keep expanding, customer design-in speed slows, or equity-compensation dilution rises further, I would view the judgment that "the current price lacks a margin of safety" as even stronger.

Comparison with indexes, risk-free yield, and other opportunities. If I had to choose only among FORM, an S&P 500 ETF, 10-year U.S. Treasuries, and other high-quality companies with much more reasonable valuations, I would not put FORM near the front. The reason is not that the company is poor. It is that it requires investors to bet simultaneously on high growth, high margins, and continued high valuation. The S&P 500 ETF offers more diversified risk exposure, while the 10-year Treasury offers a clear 4.56% yield. As an asset that would absorb long-term capital, FORM currently does not offer enough expected return to compensate for these risks. If my portfolio could hold only 5 assets, FORM at the current price would not qualify.

Investment Checklist.

This checklist is based on the company's 10-K, 10-Q, proxy statement, current market data, and industry materials.

Open questions and information boundaries. This report prioritizes the company's latest 10-K, 10-Q, proxy statement, and investor materials. However, the full real-time cross-peer comparison of EV/EBITDA, P/FCF, and ROIC for overseas peers was not recalculated one by one from all peers' latest primary filings, so it can only serve as directional support. "Peers are expensive too" cannot be treated as evidence that FORM is cheap. This limitation does not change my core conclusion, because FORM is already expensive relative to its own historical cash flow, management's target model, and conservative owner earnings.

Final investment conclusion.

【Final Rating】 Watch

【One-Sentence Investment Thesis】 FormFactor is a high-quality niche semiconductor test leader with technical barriers and customer design-in advantages, but the current price has moved far ahead of its verifiable owner earnings and conservative intrinsic value.

【Core Bull Case】 It is deeply tied to a small number of global leading customers and has lab-to-fab capability from R&D to volume production; AI, HBM, and advanced packaging create medium-term demand tailwinds; the balance sheet is solid and almost net-cash; if the new facility ramps smoothly, margins have room to improve further; and TechInsights recognition plus customer awards demonstrate strong execution.

【Core Bear Case】 The valuation is extremely high, with almost no margin of safety; revenue depends on a small number of customers and quarterly visibility is limited; historical free cash flow is not smooth, with both 2023 and 2025 very weak; GAAP operating income in 2023-2024 was affected by gains on business divestitures, which can overstate sustainable profitability; equity-incentive expansion and anti-dilution buybacks weaken the focus on per-share value.

【Key Assumptions】 HBM/AI-related demand remains strong; the new facility delivers scale effects before the end of 2026; major customers do not shift materially to competitors; the company can translate the margin improvement in its target model into real, distributable cash flow; valuation does not undergo a sharp mean reversion.

【Ideal/Fair Buy Price】 I would be more willing to study and consider buying in the $30-45 range; $45-70 can be a holding range for investors who understand the business and accept cyclicality; above $90 I view as a clearly overvalued zone. This conclusion is based on cross-checking conservative owner earnings discounting, management's target model, and the book/net-cash safety cushion.

【Target Holding Period】 If bought at a reasonable price in the future, I think the appropriate horizon should be at least 5-10 years to observe share and cash-flow delivery in advanced probe cards, HBM, and engineering test platforms. At the current price, however, it is not worth sacrificing buy discipline for the sake of being "long term."

【Expected Annualized Return】 Buying at the current price of about $124.25, my rough expectations are:

• Conservative scenario: negative return to low-single-digit negative return;

• Base scenario: 0%-4%;

• Optimistic scenario: 5%-8%. The expected return is so low because even with good operating performance, the current valuation still sets a very high hurdle for future returns.

【Maximum Loss Risk】 In the worst case, if HBM demand weakens, the company realizes only ordinary industry margins, and valuation reverts to a more common growth industrial range, FORM's share price could experience a long-term drawdown of more than 50%. Such a loss would not necessarily come from business collapse. It could simply come from an excessively high purchase price.

【Tracking Metrics】 Recommended metrics to track include: DRAM revenue mix and HBM-related order strength, recovery in Foundry & Logic revenue, the gap between GAAP and non-GAAP gross margins, Farmers Branch start-up costs and capacity utilization, operating cash flow and free cash flow, inventory and inventory write-down provisions, revenue contribution from the top two customers, equity-incentive burn rate, whether buybacks actually reduce share count, and the company's delivery against its target model.

【Signals for Reassessment】 The investment logic should be reviewed immediately if the company delivers high cash conversion for several consecutive quarters with fewer nonrecurring adjustments; if customer concentration declines and gross margin rises materially; if the share price falls sharply into the reasonable range I provide; or, conversely, if HBM demand weakens, inventory pressure rises, customer share is lost, or dilution increases further.

【Final Recommendation】 Put calmly, FORM is worth studying, but not worth buying at the current price. It is not a bad company. On the contrary, it is a highly capable company in a specific part of semiconductor testing. The issue is simply that an excellent business and an excellent investment are not the same thing; price determines the ceiling on returns. For an investor with a horizon longer than 10 years and a balanced-to-conservative risk preference, the most rational approach is not to chase the stock here, but to place FORM on a high-priority watchlist: continue tracking order quality, cash-flow delivery, and the new facility ramp, while patiently waiting for a price that provides a real margin of safety.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.